NEW YORK, March 1, 2021-- OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds. • OrbiMed Private Investments VIII invests primarily in venture capital stage opportunities in North America and Europe, with a focus on biotechnology, medical device, and diagnostics companies.